Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 45Carcinoma, Renal Cell 19Neoplasm Metastasis 16Leukemia, Myeloid, Acute 15Kidney Neoplasms 14Skin Neoplasms 11Neoplasms 10Leukemia 7Breast Neoplasms 7Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Ovarian Neoplasms 4Neuroblastoma 4Congenital Abnormalities 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Uveal Melanoma 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1

Interventions

spartalizumab 1pembrolizumab 1palbociclib 1etelcalcetide hydrochloride 1aldesleukin 1Sorafenib 1Sodium Bicarbonate 1Interleukin-2 1Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Kidney Diseases × Interleukin-2 × Clear all
NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
27 enrolled 10 charts
Genitourinary

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡